CompletedPhase 1NCT00020111
Arsenic Trioxide in Treating Young Patients With Refractory Leukemia or Lymphoma
Studying Acute myeloid leukemia with t(9;22)(q34.1;q11.2)
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- Frank M. Balis, MD, MDNational Cancer Institute (NCI)
- Intervention
- arsenic trioxide(drug)
- Eligibility
- 2-21 years · All sexes
- Timeline
- 2000
Study locations (30)
- Arkansas Cancer Research Center at University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
- City of Hope Comprehensive Cancer Center, Duarte, California, United States
- Rebecca and John Moores UCSD Cancer Center, La Jolla, California, United States
- Children's Hospital Los Angeles, Los Angeles, California, United States
- Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
- Children's Hospital of Orange County, Orange, California, United States
- Lucile Packard Children's Hospital at Stanford University Medical Center, Palo Alto, California, United States
- UCSF Comprehensive Cancer Center, San Francisco, California, United States
- County of Los Angeles Harbor-UCLA Medical Center, Torrance, California, United States
- Children's National Medical Center, Washington D.C., District of Columbia, United States
- AFLAC Cancer Center and Blood Disorders Service of Children's Healthcare of Atlanta - Scottish Rite Campus, Atlanta, Georgia, United States
- Children's Memorial Hospital - Chicago, Chicago, Illinois, United States
- Riley Children Cancer Center at Riley Hospital for Children, Indianapolis, Indiana, United States
- Kansas Masonic Cancer Research Institute at the University of Kansas Medical Center, Kansas City, Kansas, United States
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00020111 on ClinicalTrials.govOther trials for Acute myeloid leukemia with t(9;22)(q34.1;q11.2)
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT05031897Two Step Haplo With Radiation ConditioningThomas Jefferson University
- ACTIVE NOT RECRUITINGPHASE2NCT04188405Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leukemia or Myeloid Blast Phase or Accelerated Phase Chronic Myelogenous LeukemiaM.D. Anderson Cancer Center
- ACTIVE NOT RECRUITINGPHASE1NCT02530034Hu8F4 in Treating Patients With Advanced Hematologic MalignanciesM.D. Anderson Cancer Center
- RECRUITINGPHASE1NCT03630991Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing ChemotherapyM.D. Anderson Cancer Center
- ACTIVE NOT RECRUITINGPHASE2NCT03147612Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic LeukemiaM.D. Anderson Cancer Center
- ACTIVE NOT RECRUITINGPHASE2NCT02861417Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer Undergoing Donor Stem Cell TransplantM.D. Anderson Cancer Center
See all trials for Acute myeloid leukemia with t(9;22)(q34.1;q11.2) →